Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | PEPD | P12955 | 1/20 | 0.36 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.34 |
| ▸ | GRM3 | Q14832 | 1/20 | 0.34 |
| ▸ | ADAM10 | O14672 | 1/20 | 0.34 |
| ▸ | MMP2 | P08253 | 1/20 | 0.34 |
| ▸ | MMP9 | P14780 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | APLNR | P35414 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16300573 | 0.86 | PEPD (0.37) | ATMPEPDADAM10MMP2MMP9 | |
| SCHEMBL16349111 | 0.86 | PEPD (0.37) | ATMPEPDADAM10MMP2MMP9 | |
| SCHEMBL22845171 | 0.84 | ATM (0.35) | ATMADAM10MMP2MMP9CYP2C19 | |
| SCHEMBL25364146 | 0.84 | GRM2 (0.36) | PEPDGRM2GRM3CYP2C19 | |
| SCHEMBL21806853 | 0.84 | GRM2 (0.36) | PEPDGRM2GRM3CYP2C19 | |
| SCHEMBL28152017 | 0.83 | ATM (0.42) | ATMGRM2GRM3CYP2C19POLB | |
| SCHEMBL22831693 | 0.83 | CYP2D6 (0.46) | ATMCYP2C19SMN1; SMN2 | |
| SCHEMBL19075599 | 0.80 | RIPK1 (0.34) | PEPDGRM2GRM3CYP2C19 | |
| SCHEMBL16300567 | 0.79 | PEPD (0.33) | ATMPEPD | |
| SCHEMBL16300561 | 0.79 | PEPD (0.33) | ATMPEPD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3166939-B1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH INC (US) | 2019-06-05 | — | — | EP | disclosed |
| US-20170190662-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2017-07-06 | — | — | US | disclosed |
| WO-2016007534-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2016-01-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170190662-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | RDX, C1R, MTX1 | ATM 4395/4885PEPD 1385/4885GRM2 4008/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.